US Pharmaceuticals & Biotechnology: UBS Bio Catalyst Watch

Research evidence excerpt

US Pharmaceuticals & Biotechnology: UBS Bio Catalyst Watch

US Pharmaceuticals & Biotechnology UBS Research

Catalysts grouped by expected stock impact

We summarize below select catalysts for the next ~90 days by impact across our

coverage universe. We believe high impact catalysts could move stocks by 5% or more

for pharma and large-cap biotech and 10-30% or more for SMID-caps.

High Impact:

ACAD: Topline results in Alzheimer's disease psychosis (ADP) between August-

October 2026.

AMGN: Read through from NVS Lp(a) Phase III trial coming in H2 (we est mid year)

ANAB: Updates from the ongoing litigation with GSK with full trial scheduled for

July 14-17

BHVN: Topline data for Ph 3 focal epilepsy trial in H2/26.

BMY: Phase III event-driven readouts in SSP & SSP (LIBREXIA)in H2/26

BMY: Phase III ALOFT-IPF readout in IPF in H2/26

CGEM: CLN-978 Phase I data from the multi-dose cohort of the RA study in Q3/26

CGON: Topline data for Phase III PIVOT-006 trial in IR NMIBC in Q3/26

EXEL: Topline data for Ph3 STELLAR-304 trial in nccRCC coming in Q2/26.

INCY: MF naïve patient 1L data (mono & combo) in H2/26.

JAZZ: PDUFA date for Ziihera's sBLA in 1L HER2+ GEA. Scheduled for August 25.

KOD: Topline data for Phase III DAYBREAK wet AMD trial of tarcocimab QM-

Q6M vs. Eylea 2mg vs. KSI-501 in September

MPLT: Phase II ZEPHYR trial topline data in August 2026.

MRNA: Phase III combo data with Keytruda in adjuvant melanoma in H2/26

OLMA: Phase III 2L oral SERD HR+ BC data in Fall 2026

PFE: Potential Phase I initial amylin combination data in 2026

SRRK: PDUFA for Apitegromab for SMA on Sept 30th 2026

TEVA: FDA approval/launch of olanzapine in schizophrenia in H2/26.

UTHR: Legal update from the PH-ILD patent case (patent '327) vs. LQDA (not

covered). Update expected anytime.

Moderate Impact: